Press release ·
Constitutional Court sets landmark precedent in a patent infringement case
After five years of litigation, the Bogotá Superior Court ruled that Dr. Guillermo Mejía Mejía's patent was infringed, in compliance with an unprecedented ruling of the Constitutional Court.
Tobos Abogados SAS and Uprolab SAS are pleased to announce that, after five years of litigation, the Civil Chamber of the Superior Court of the Judicial District of Bogotá has ruled that the Colombian patent covering the procedure for obtaining hepatic and splenic porcine‑derived polypeptides, invented by Dr. Guillermo Mejía Mejía, was infringed, and ordered the infringers to immediately cease commercialization of the products that violated said patent.
The Court’s decision complies with an unprecedented ruling issued by the Constitutional Court.
As a result, Uprolab SAS is confirmed as the licensee of Dr. Mejía’s patent, and the UPRONE line is established as the only one containing polypeptides obtained through the patented procedure.
This ruling represents a significant victory for the protection of intellectual property in the sector and reaffirms the importance of scientific innovation supported by solid legal mechanisms. It also validates the trajectory of Tobos Abogados SAS as a firm committed to the defense of industrial property in Colombia.
The process was demanding and sustained through the final instance. Today, we receive this decision with satisfaction and with the conviction of having acted with legal rigor and responsibility toward innovation and the industry.
We extend our gratitude to the individuals, companies, and colleagues who accompanied us throughout this process and trusted in the strategic importance of this patent for the country and for the development of the sector.